Table 1 Characteristics of BCRL patients in the retrospective cohort

Subjects

326

235

91

Age^#

48(43–57)

47(43–55)

52(44–61)

Tumor size^#

20(5–30)

20(5–30)

23(6–35)

Positive lymph nodes^#

2(0–4)

2(0–3)

0(0–1)

Total lymph node dissection^#

18(15–22)

18(15–22)

19(16–22)

Cycles^#

6(4–8)

6(4–8)

6(6–8)

Serum cholesterol^#

5.107(4.315–5.869)

5.104(4.268–5.830)

5.126(4.389–6.040)

BMI^#

24.53(22.43–26.86)

24.41(22.27–26.75)

24.77(22.77–27.24)

IPNs dissection^*

 Yes

60 (18.4)

18 (7.7)

42 (46.2)

 No

266 (81.6)

217 (92.3)

49 (53.8)

ER^*

 Positive

216 (66.3)

153 (65.1)

63 (69.2)

 Negative

110 (33.7)

82 (34.9)

28 (30.8)

PR^*

 Positive

183 (56.1)

125 (53.2)

58 (63.7)

 Negative

143 (43.9)

110 (46.8)

33 (36.3)

Ki-67^*

 Positive

164 (50.3)

121 (51.5)

43 (47.3)

 Negative

162 (49.7)

114 (48.5)

48 (52.7)

HER2^*

 Positive

112 (34.4)

81 (34.5)

31 (34.1)

 Negative

214 (65.6)

154 (65.5)

60 (65.9)

Neoadjuvant chemotherapy^*

 Yes

106 (32.5)

76 (32.3)

30 (33.0)

 No

220 (67.5)

159 (67.7)

61 (67.0)

Docetaxel^*

 Yes

278 (85.3)

196 (83.4)

82 (90.1)

 No

48 (14.7)

39 (16.6)

9 (9.9)

Chemotherapy^*

 Yes

301 (92.3)

215 (91.5)

86 (94.5)

 No

25 (7.7)

20 (8.5)

5 (5.5)

Radiotherapy^*

 Yes

234 (71.8)

160 (68.1)

74 (81.3)

 No

92 (28.2)

75 (31.9)

17 (18.7)

Education level^*

 High-Bachelor’s degree or more

204 (62.6)

170 (72.3)

34 (37.4)

 Low-Associates degree or less

122 (37.4)

65 (27.7)

57 (62.6)

Hypertension^*

 Yes

56 (17.2)

35 (14.9)

21 (23.1)

 No

270 (82.8)

200 (85.1)

70 (76.9)